scholarly journals Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 133
Author(s):  
Claudia Sommerer ◽  
Anita Schmitt ◽  
Angela Hückelhoven-Krauss ◽  
Thomas Giese ◽  
Thomas Bruckner ◽  
...  
Keyword(s):  
T Cells ◽  
Kidney Transplantation ◽  
T Cell ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Solid Organ ◽  
Peptide Vaccination ◽  
Stage Renal Disease ◽  
End Stage ◽  
Cmv Reactivation

Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.

scholarly journals End-stage renal disease, dialysis, kidney transplantation and their impact on CD4+T-cell differentiation

Immunology ◽  
2018 ◽  
Vol 155 (2) ◽  
pp. 211-224 ◽  
Author(s):  
Matthias Schaier ◽  
Angele Leick ◽  
Lorenz Uhlmann ◽  
Florian Kälble ◽  
Christian Morath ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Cell Differentiation ◽  
T Cell ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
T Cell Differentiation ◽  
Cd4 T Cell ◽  
Stage Renal Disease ◽  
End Stage

Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy

2018 ◽  
Vol 93 (6) ◽  
pp. 1452-1464 ◽  
Author(s):  
Sybille Landwehr-Kenzel ◽  
Anne Zobel ◽  
Henrike Hoffmann ◽  
Niels Landwehr ◽  
Michael Schmueck-Henneresse ◽  
...  
Keyword(s):  
T Cells ◽  
Kidney Transplantation ◽  
Cell Therapy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Ex Vivo ◽  
Autologous Cell ◽  
Autologous Cell Therapy ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus

2021 ◽  
Vol 22 (6) ◽  
pp. 2975
Author(s):  
Erasmia Sampani ◽  
Dimitra-Vasilia Daikidou ◽  
George Lioulios ◽  
Aliki Xochelli ◽  
Zoi Mitsoglou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cell Immunity ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End-stage renal disease (ESRD) is associated with alterations in T-cell immunity, including increased CD28null and reduced regulatory T cells (Tregs). However, whether immune disturbances are due to ESRD or primary disease is not yet clear. As diabetes mellitus is the leading cause of ESRD, we evaluated its impact on the immune profile of ESRD patients. Methods: CD28null, Tregs, and natural killer cells were initially analyzed by flow cytometry in 30 predialysis ESRD patients due to diabetes (DM), 30 non-DM (NDM), and 25 healthy controls. Measurements were repeated after 6 months on hemodialysis (HD) or peritoneal dialysis (CAPD). Results: The percentage of CD4 + CD28null cells, CD8 + CD28null cells, and Tregs showed significant differences in DM, NDM, and controls; mean rank 33.71 vs. 25.68 vs. 18.88, p = 0.006, 37.79 vs. 28.82 vs. 17.08, p = 0.008, and 20.79 vs. 26.12 vs. 41.33, p = 0.001, respectively. DM vs. NDM had increased CD4 + CD28null and CD8 + CD28null cells, 11.5% (1.5%–24%) vs. 4.1% (0–42.3%), p = 0.02 and 61.3% (24%–76%) vs. 43% (5.7%–85%), p = 0.04, respectively. After 6 months on HD but not CAPD, DM showed a significant further increase in CD4 + CD28null cells, from 30 (14–100) to 52.7 (15–203), p = 0.02; and CD8 + CD28null cells, from 137 (56–275) to 266 (103–456), p = 0.01. Conclusions: Diabetes mellitus affects T-cell subtypes even at predialysis stage, though changes become more prominent after commencement on HD.

scholarly journals Significant Decrease in Plasma N-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation

2014 ◽  
Vol 37 (6) ◽  
pp. 1075-1079 ◽  
Author(s):  
Yosuke Suzuki ◽  
Fumihiko Katagiri ◽  
Fuminori Sato ◽  
Kanako Fujioka ◽  
Yukie Sato ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Proline Level ◽  
Stage Renal Disease ◽  
End Stage

Economic Evaluation of Kidney Transplantation versus Hemodialysis in Patients with End-Stage Renal Disease in Hungary

2001 ◽  
Vol 11 (3) ◽  
pp. 188-193 ◽  
Author(s):  
Zoltán Kaló ◽  
Jeno Járay ◽  
Júlia Nagy
Keyword(s):  
Kidney Transplantation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cost Effective ◽  
Effective Option ◽  
Hungarian Population ◽  
Cadaveric Kidney ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Cost

Background— Kidney transplantation is generally acknowledged as the more clinically effective and more cost-effective option in managing patients with end-stage renal disease, compared with dialysis. This study looked for confirmatory evidence in a Hungarian population. Methods— Patients (n = 242) with end-stage renal disease who received cadaveric kidney transplantation during 1994 were followed up for 3 years. They were compared with patients (n = 840) receiving hemodialysis who were on a waiting list for transplantation. Data were collected retrospectively. Treatments were compared for clinical efficacy and for cost-effectiveness. Results— At month 36, the standard mortality hazard function was 3.5 times higher in the group receiving hemodialysis ( P<.0001) than in the transplant recipients. Average treatment costs per patient over the 3 years were also significantly higher ( P<.0001) in the hemodialysis group than in the group that received transplants. The cost of 1 year gained by transplantation was significantly less ( P<.0001) than the cost associated with hemodialysis. Conclusions— Compared with hemodialysis, kidney transplantation provides greater survival benefits to patients with end-stage renal disease, at less cost.

Sign in / Sign up

Export Citation Format

Share Document